Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".

Clin Mol Hepatol · 2025 · PMC11791597 · PMID 39228069

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A phase 2 study (KEYNOTE-224) using the anti-PD-1 antibody pembrolizumab as second-line therapy also showed a trend towards higher ORR in patients with high PD-L1 expression in tumor tissue compared to those with low PD-L1 expression ( Table 1 ) [ 17 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.